publication date: Jul. 28, 2017

In Brief Carlos Arteaga to head UT Southwestern Simmons Comprehensive Cancer Center

Carlos Arteaga, a breast cancer expert, was named director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.

His appointment begins Sept. 1.

Arteaga comes to UT Southwestern from the Vanderbilt-Ingram Cancer Center, where he has been on faculty since 1989.

At Vanderbilt, he serves as director of the Center for Cancer Targeted Therapies and the Breast Cancer Program, associate director for Translational & Clinical Research, and professor of medicine (oncology) and cancer biology. He also holds the Donna S. Hall Chair in Breast Cancer.

Arteaga led a research program that included a long-standing NCI Specialized Programs of Research Excellence award in breast cancer research, along with research into drug-resistance in breast cancer and genotype-driven trials in cancer care.

At UT Southwestern, Arteaga also will serve as associate dean for the oncology program at UT Southwestern Medical School and will hold the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology.

UT Southwestern receives more than $100 million annually for cancer research from NCI and other NIH and peer-reviewed funding agencies, as well as the Cancer Prevention and Research Institute of Texas.

 

Larry Copeland appointed president of GOG Foundation

Philip DiSaia resigned as president of the GOG Foundation Inc. and as one of the three group chairs of NRG Oncology.

Larry … Continue reading Carlos Arteaga to head UT Southwestern Simmons Comprehensive Cancer Center

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.